Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
about
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety and efficacy of subcuta ...... controlled trial (faSScinate).
@en
Safety and efficacy of subcuta ...... II randomised controlled trial
@nl
type
label
Safety and efficacy of subcuta ...... controlled trial (faSScinate).
@en
Safety and efficacy of subcuta ...... II randomised controlled trial
@nl
prefLabel
Safety and efficacy of subcuta ...... controlled trial (faSScinate).
@en
Safety and efficacy of subcuta ...... II randomised controlled trial
@nl
P2093
P2860
P1476
Safety and efficacy of subcuta ...... controlled trial (faSScinate).
@en
P2093
Angelika Jahreis
Celia J F Lin
Christopher P Denton
Daniel E Furst
Dinesh Khanna
Gerhard Fierlbeck
Helen Spotswood
Jacob M van Laar
Jeffrey Siegel
Laura Burke
P2860
P304
P356
10.1136/ANNRHEUMDIS-2017-211682
P407
P50
P577
2017-10-24T00:00:00Z